

Impact Patients toward Active Lives

● Greater than 500,000 patients using Bioventus Products

Achieve Financial Goals

● Revenue \$402.5M

● EBITDA \$79M

Talent/Cultural Development

- Promote career growth opportunities with at least a 50% internal promotion rate
- Commence Diversity, Inclusion, Equity Council
- Reduce number of compliance investigations by 10%

Drive Organic Growth to High Single Digits

- “Relaunch” Exogen with Metatarsal PMA Supplement – Q3
- Launch OsteoAmp Flowable – Q3

Build Organic Growth through Research and Development and Clinical Data

- BONES scaphoid patients followed up (Q3) and database lock (Q4)
- MOTYS phase 2 clinical study initiated OUS – Q3
- ProCuff completion of large animal study

Achieve Double Digit Growth through Tuck In Acquisitions

- Complete 16 early diligence processes and at least 3 non-binding term sheets
- Develop business development pipeline for OUS – Europe and Asia

Expand Globally in High Opportunity Markets

- China CFDA meeting – Q2
- Launch Durolane in Middle East

Operational Excellence

- Process conversion to Exogen claims management system (Brightree) – Q4
- Achieve product safety-related complaint rates below designated levels by product: Exogen </1%; HA </0.05%; Bone Grafts </0.4%



Impact Patients toward Active Lives
Achieve Financial Goals

● Greater than 500,000 patients using Bioventus Products
● Revenue \$402.5M ● EBITDA \$79M

Bioness 2021 Rest of Year

- TalisMann 510(k) Clearance – Q4
- StimRouter Plus Launch – Q4
- Commence Trial Lead Project and pre-sub FDA Meeting – Q4
- MDR Audit – minor observations only – Q3
- L360 Commercial Pilot in Ortho – Q4
- Establish US Vector Market Share Leadership – Q4

